Cover
| Cover | Oct. 08, 2021 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | This Amendment No. 1 to our Current Report on Form 8-K (this “Amendment”) is being filed by BIMI International Medical Inc. (the “Company”) for the purpose of amending Item 9.01 of that certain Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission (“SEC”) on October 12, 2021 (the “Original Form 8-K”) in connection with the October 8, 2021 completion of the acquisition of Chongqing Zhuoda Pharmaceutical Co., Ltd. (“Zhuoda”). The Zhuoda acquisition was first announced on September 14, 2021. As indicated in the Original Form 8-K, this Amendment is being filed to provide the financial statements and pro forma financial information required by Items 9.01(a) and (b) of Form 8-K, which were not previously filed with the Original Form 8-K as permitted by the rules of the SEC. |
| Document Period End Date | Oct. 8, 2021 |
| Entity File Number | 001-34890 |
| Entity Registrant Name | BIMI International Medical Inc. |
| Entity Central Index Key | 0001213660 |
| Entity Tax Identification Number | 02-0563302 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 9th Floor, Building 2 |
| Entity Address, Address Line Two | Chongqing Corporation Avenue |
| Entity Address, Address Line Three | Yuzhong District |
| Entity Address, City or Town | Chongqing |
| Entity Address, Country | CN |
| Entity Address, Postal Zip Code | 116000 |
| City Area Code | 8604 |
| Local Phone Number | 1182209211 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common stock, $0.001 par value |
| Trading Symbol | BIMI |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |